AbbVie FY2027 Earnings Forecast Reduced by Erste Group Bank

AbbVie Inc. (NYSE:ABBV) – Equities researchers at Erste Group Bank cut their FY2027 earnings per share estimates for shares of AbbVie in a report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the company will earn $16.28 per share for the year, down from their prior estimate of $16.34. Erste Group Bank has a “Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $13.92 per share.

Several other equities analysts have also recently issued reports on the company. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and boosted their target price for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Guggenheim reiterated a “buy” rating and issued a $288.00 price target on shares of AbbVie in a report on Friday, October 9th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Finally, Piper Sandler upped their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $279.86.

AbbVie Stock Down 0.0%

Shares of AbbVie stock opened at $286.70 on Monday. The business’s 50 day simple moving average is $267.66 and its two-hundred day simple moving average is $236.20. AbbVie has a one year low of $190.75 and a one year high of $291.40.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the company earned $2.97 earnings per share. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

Hedge Funds Weigh In On AbbVie

Several hedge funds have recently added to or reduced their stakes in the company. Lifelong Wealth Advisors Inc. raised its stake in AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after buying an additional 36 shares in the last quarter. IMG Wealth Management Inc. boosted its position in AbbVie by 22.8% during the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock valued at $51,000 after acquiring an additional 36 shares in the last quarter. James T. Borello RIA increased its holdings in shares of AbbVie by 3.5% in the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock valued at $312,000 after acquiring an additional 40 shares during the period. ACT Advisors LLC. increased its holdings in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after acquiring an additional 41 shares during the period. Finally, SYM FINANCIAL Corp raised its position in shares of AbbVie by 1.0% in the 3rd quarter. SYM FINANCIAL Corp now owns 4,190 shares of the company’s stock worth $1,096,000 after acquiring an additional 42 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by insiders.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a biologics license application to the FDA for etentamig, a next-generation BCMA×CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, the treatment significantly improved overall response rate and progression-free survival versus available standard therapies, supporting potential pipeline diversification beyond immunology. AbbVie Submits BLA for Etentamig
• Positive Sentiment: The FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn’s disease, including an on-body injector that enables an at-home treatment start. The approval could improve patient convenience and help support continued growth of AbbVie’s key immunology franchise. FDA Approves SKYRIZI Crohn’s Disease Regimen
• Positive Sentiment: Goldman Sachs raised its AbbVie price target to $294, while reports that Citadel has built an approximately $900 million position may reinforce institutional confidence. Analysts also identify SKYRIZI and RINVOQ as important growth drivers.
• Neutral Sentiment: Options markets imply an approximately 5% potential move around the October 30 earnings release. AbbVie previously exceeded quarterly EPS and revenue expectations, but investors will focus on SKYRIZI and RINVOQ sales, expenses and updated guidance.
• Negative Sentiment: Some analysts view ABBV as fully valued after its strong run, with rising expenses, declining estimates and intensifying competition creating near-term risks. Erste Group Bank also reduced its EPS forecast, potentially limiting upside ahead of earnings.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.